Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock
Medtronic's stock lags peers due to growth challenges in the diabetes and hypertension markets. See why we recommend a sell ...
Gov. Ned Lamont unveils proposals to tackle prescription drug costs
There’s an ongoing push to improve health care affordability and reduce out-of-pocket costs, especially for prescription ...
Embecta raises FY2025 adjusted EBITDA margin guidance to 37% amid cost-cutting and debt reduction focus
Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...
cnbctv181h
Caplin Point Q3 Results | Net profit rises 19% on strong margins, product launches
The EBITDA margin stood at 33% in the reporting quarter compared to 32.7% a year ago. Shares of Caplin Point Laboratories Ltd ...
Minnesota’s electric co-ops, biofuels stand to gain from Inflation Reduction Act
As a leader in renewable energy resources, Minnesota could have an outsized impact from the climate change-fighting provisions of the Inflation Reduction Act. The bill, signed into law by ...
Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
LOOKING BACK
H.A. Roepke has sold his harness shop to Andrew Amundson. Oscar Schirber, who owned an interest in the stock, has withdrawn his portion and Mr. Amundson will conduct the ...